Sustainability | September 17, 2024
Aragen receives SBTi approval for its greenhouse gas emission reduction targets
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Lokavant provides clinical trial intelligence
Subscribe To Our Newsletter & Stay Updated
